



Contact:
Nancy F. Morter
Dilon Technologies Inc.
C: 757-589-3914
O: 757-269-4910 x 302
E: nfmorter@dilon.com
www.dilon.com

**Newly Appointed Dilon Technologies President & CEO Robert G. Moussa
Sees BSGI as "...Major weapon in the battle against cancer"**

NEWPORT NEWS, VIRGINIA: 2/07/08 – Dilon Technologies, makers of a gamma imaging system optimized for early breast cancer detection, has appointed Robert G. Moussa to the position of President and Chief Executive Officer.

Moussa has a long and successful record in the medical device industry having held a number of senior positions at both Sherwood Medical Industries and Mallinckrodt Medical – a health care corporation he ran as CEO for a number of years. At Mallinckrodt, Moussa grew revenues from \$350 million to \$1.2 billion in a four-year period and increased the operating margins from 18 percent 22 percent during the same period. Additionally, he has successfully launched a number of new products in the diagnostic, nuclear medicine and medical device markets.

Dilon "the standard of care"

Regarding Dilon Moussa commented, "Dilon has advanced technology that will make it a major weapon in the battle against cancer. Based upon existing clinical results, it will become the standard or care as an adjunct diagnostic tool in the diagnosis of breast cancer."

4-Point Strategy

Under Moussa's leadership, Dilon will adopt a 4-point strategy to increase market share. The strategy includes:

1. Expansion of the established installed base in the US through strategic use of sales and distribution.
2. Initiating a major international expansion strategy. This is based on Dilon's international potential of being at least as large as that in the US.
3. Working with the Medical Establishment, expand the capabilities and indications for the existing BSGI product.
4. Pursue acquisitions of products, technologies and companies that offer a strategic fit with Dilon.



Moussa added, "I am confident that by adopting and accelerating these measures, we will achieve the objective of making Dilon the standard of care in the diagnostic field."

About Dilon Technologies Inc.

Dilon Technologies Inc. is bringing innovative new medical products to the market based on research conducted at leading national research laboratories. Dilon's cornerstone product is the Dilon 6800 Gamma Camera - a high-resolution, anatomic-specific gamma camera, which is now being used to perform Breast-Specific Gamma Imaging (BSGI), a molecular imaging technique that images the metabolic activity of breast lesions through radiotracer uptake. Several leading medical centers around the country are now offering BSGI to their patients, including: Beth Israel Medical Center, New York; George Washington University Medical Center, Washington, D.C.; Alexian Brothers Medical Center, Chicago; Methodist Hospital, Philadelphia; and West Valley Imaging, Las Vegas.

To find out more about BSGI or the Dilon 6800 Gamma Camera please visit www.dilon.com

###